Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 9/20 | 0.45 |
| ▸ | UTS2R | Q9UKP6 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.41 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666601 | 0.93 | UTS2R (0.48) | CHRNA7UTS2REPHX2TEAD1PRKAA2 | |
| SCHEMBL649121 | 0.90 | CHRNA7 (0.44) | CHRNA7UTS2R | |
| SCHEMBL649739 | 0.89 | UTS2R (0.51) | CHRNA7UTS2RTEAD1 | |
| SCHEMBL647341 | 0.86 | UTS2R (0.52) | UTS2RTEAD1DRD4 | |
| SCHEMBL647504 | 0.83 | UTS2R (0.46) | CHRNA7UTS2RTEAD1HTR3A | |
| SCHEMBL649439 | 0.83 | DRD4 (0.49) | UTS2RDRD4 | |
| SCHEMBL648321 | 0.83 | UTS2R (0.56) | UTS2RPRKAA2DRD4 | |
| SCHEMBL651149 | 0.83 | UTS2R (0.56) | CHRNA7UTS2RTEAD1HTR3A | |
| SCHEMBL650752 | 0.82 | UTS2R (0.45) | UTS2RDRD4 | |
| SCHEMBL648492 | 0.81 | UTS2R (0.54) | UTS2RDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231600-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2010-09-29 | — | — | EP | claimed |
| WO-2009065131-A1 | CARBOXAMIDE, SULFONAMIDE AND AMINE COMPOUNDS FOR METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | claimed |